{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:32:26Z","timestamp":1793770346713,"version":"4.6.1"},"reference-count":36,"publisher":"FapUNIFESP (SciELO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz. J. Biol."],"abstract":"<jats:p>Abstract Yeast infections have acquired great importance due to increasing frequency in immunocompromised patients or patients undergoing invasive diagnostic and therapeutic techniques, and also because of its high morbidity and mortality. At the same time, it has been seen an increase in the emergence of new pathogenic species difficult to diagnose and treat. The aim of this study was to determine the in vitro susceptibility of 89 yeasts from different sources against the antifungals amphotericin B, voriconazole, fluconazole and flucytosine, using the VITEK\u00ae 2 Compact system. The antifungal susceptibility was performed automatically by the Vitek\u00ae 2 Compact system. The origin of the yeasts was: Group 1 - microbiota of wild animals (W) (26\/89), 2 - cow\u2019s milk with subclinical mastitis (M) (27\/89) and 3 - hospital enviorment (H) (36\/89). Of the 89 yeasts submitted to the Vitek\u00ae 2 test, 25 (20.9%) were resistant to fluconazole, 11 (12.36%) to amphotericin B, 3 (3.37%) to voriconazole, and no sample was resistant to flucytosine. Regarding the minimum inhibitory concentration (MIC), fluconazole showed an MIC between 1 and 64 mg\/mL for the three groups, voriconazole had an MIC between 0.12 and 8 mg\/mL, amphotericin B had an MIC between 0.25 and 4 mg\/mL for group H and group W respectively, between 0.25 and 16 mg\/mL for group M and flucytosine had an MIC equal to 1\u03bcg\/mL for all groups. The yeasts isolated from the H group showed the highest resistance to fluconazole 12\/89 (13.49%), followed by group W (7.87%) and group M (5.62%). The more resistant group to voriconazole was followed by the M and H groups, the W group showed no resistance to this antifungal. Group H was the least resistant (2.25%) to amphotericin.<\/jats:p>","DOI":"10.1590\/1519-6984.04916","type":"journal-article","created":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T01:28:41Z","timestamp":1499131721000},"page":"68-75","source":"Crossref","is-referenced-by-count":3,"title":["Antifungal susceptibility profile of diferent yeasts isolates from wild animals, cow\u2019s milk with subclinical mastitis and hospital environment"],"prefix":"10.1590","volume":"78","author":[{"given":"J. F.","family":"Mendes","sequence":"first","affiliation":[{"name":"Universidade Federal de Pelotas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. L.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pelotas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. F.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pelotas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. A.","family":"Esteves","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pelotas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. H.","family":"Freitas","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pelotas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P. V.","family":"Villarreal","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pelotas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R. B.","family":"Mello","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C. A.","family":"Meireles","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pelotas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. S.","family":"Nascente","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pelotas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1439-0507.2008.01637.x","article-title":"Neonatal candidemia in Kuwait: a 12- year study of risk factors, species spectrum and antifungal susceptibility","volume":"52","author":"AL-SWEIH N.","year":"2009","journal-title":"Mycoses"},{"key":"ref2","series-title":"Vitek 2TM: Instrument user manual","first-page":"185","year":"2008"},{"issue":"3","key":"ref3","first-page":"487","article-title":"Effects of fluoxetine on the anticonvulsant action of valproate and ethosuximide in mouse model of myoclonic convulsions","volume":"19","author":"BOROWICZ K.K.","year":"2012","journal-title":"Annals of Agricultural and Environmental Medicine"},{"key":"ref4","series-title":"M27-A3: Reference method for broth dilution antifungal susceptibility testing of yeasts - approved standard-third edition","year":"2008","edition":"3rd"},{"key":"ref5","series-title":"M27-S4: Reference method for broth dilution antifungal testing of yeats; fourth informal supplement","year":"2012"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(08)70179-7","article-title":"Cancer survival in five continents: a worldwide population-based study","volume":"9","author":"COLEMAN M.P.","year":"2008","journal-title":"The Lancet Oncology"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1590\/S0037-86822007000300016","article-title":"Candid\u00faria: uma abordagem cl\u00ednica e terap\u00eautica","volume":"40","author":"COLOMBO A.L.","year":"2007","journal-title":"Revista da Sociedade Brasileira de Medicina Tropical"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1590\/S0365-05962004000600005","article-title":"Identifica\u00e7\u00e3o de esp\u00e9cies de Candida e susceptibilidade antif\u00fangica in vitro: estudo de 100 pacientes com candid\u00edases superficiais","volume":"79","author":"CROCCO E.L.","year":"2004","journal-title":"Anais Brasileiros de Dermatologia"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1470-9465.2004.00838.x","article-title":"Voriconasole a new therapeutic agent with an extended spectrum of antifungal activity","volume":"10","author":"DONNELLY J.P.","year":"2004","journal-title":"Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1590\/S0037-86822010000600014","article-title":"Aspectos micol\u00f3gicos e suscetibilidade in vitro de leveduras do g\u00eanero Candida em pacientes HIV-positivos provenientes do Estado de Mato Grosso","volume":"43","author":"FAVALESSA O.C.","year":"2010","journal-title":"Revista da Sociedade Brasileira de Medicina Tropical"},{"issue":"3","key":"ref11","first-page":"229","article-title":"Prevalence and susceptibility of vaginal yeast","volume":"40","author":"GALLE L.C.","year":"2009","journal-title":"Jornal Brasileiro de Patologia"},{"issue":"3","key":"ref12","first-page":"223","article-title":"Identification and susceptibility profile of Candida spp. isolated from urine of patients with Candiduria em Iguatu-Cear\u00e1","volume":"42","author":"GOMES L.C.","year":"2010","journal-title":"Revista Brasileira de Analises Clinicas"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1590\/S1519-69842010000500022","article-title":"Antimicrobial potential of some plant extracts against Candida species","volume":"70","author":"H\u00d6FLING J.F.","year":"2010","journal-title":"Brazilian Journal of Biology = Revista Brasileira de Biologia"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1128\/JCM.39.9.3247-3253.2001","article-title":"Evaluation of the VITEK 2 System for the Identification and Susceptibility Testing of Three Species of Nonfermenting Gram-Negative Rods Frequently Isolated from Clinical Samples","volume":"39","author":"JOYANES P.","year":"2001","journal-title":"Journal of Clinical Microbiology"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijantimicag.2003.11.002","article-title":"Empirical antifungal therapy","volume":"23","author":"KLASTERSKY J.","year":"2004","journal-title":"International Journal of Antimicrobial Agents"},{"key":"ref16","series-title":"Antimicrobial pharmacodynamics in theory and clinical practice","first-page":"315","volume-title":"Antifungal pharmacodynamics","author":"KLEPSER M.","year":"2002"},{"issue":"1","key":"ref17","first-page":"106","article-title":"Aspects of the yeast Candida linked to nosocomial infections","volume":"64","author":"LE\u00c3O R.E.","year":"2004","journal-title":"NewsLab"},{"issue":"7","key":"ref18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0213-005X(03)72964-4","article-title":"Antif\u00fangicos de uso sist\u00e9mico","volume":"21","author":"LUMBRERAS C.","year":"2003","journal-title":"Enfermedades Infecciosas y Microbiologia Clinica"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.riam.2010.03.007","article-title":"Oral Candida carriage of patients attending a dental clinic in Braga, Portugal","volume":"27","author":"MARTINS M.","year":"2010","journal-title":"Revista Iberoamericana de Micologia"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1590\/S1517-83822014005000018","article-title":"Use of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species","volume":"44","author":"MELHEM M.S.","year":"2014","journal-title":"Brazilian Journal of Microbiology"},{"issue":"Pt2","key":"ref21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1099\/jmm.0.46817-0","article-title":"Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study","volume":"56","author":"MOKADDAS E.M.","year":"2007","journal-title":"Journal of Medical Microbiology"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1590\/1519-6984.07415","article-title":"Quercetin and rutin as potential agents antifungal against Cryptococcus spp","volume":"76","author":"OLIVEIRA V.M.","year":"2016","journal-title":"Brazilian Journal of Biology = Revista Brasileira de Biologia"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/JCM.01178-10","article-title":"Can we use imipenem and meropenem Vitek 2 MICs for detection of suspected KPC and other-carbapenemase producers among species of Enterobacteriaceae?","volume":"49","author":"PASTERAN F.","year":"2011","journal-title":"Journal of Clinical Microbiology"},{"key":"ref24","series-title":"Identifica\u00e7\u00e3o Molecular de Candidoses Invasivas no Centro Hospitalar Cova da Beira, E.P.E: M\u00e9todos Convencionais vs. M\u00e9todos Moleculares","author":"PEREIRA A.P.V.","year":"2010"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1128\/AAC.01079-10","article-title":"Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009","volume":"55","author":"PFALLER M.A.","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1086\/313749","article-title":"Practice guidelines for the treatment of candidiasis","volume":"30","author":"REX J.H.","year":"2000","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"},{"issue":"3","key":"ref27","first-page":"73","article-title":"Epidemiology of candidemia","volume":"17","author":"SANDVEN P.","year":"2000","journal-title":"Revista Iberoamericana de Micologia"},{"key":"ref28","first-page":"1","author":"SANTOS L.S.","year":"2009"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1590\/S1806-37132013000500013","article-title":"Cryptococcosis, silicosis, and tuberculous pseudotumor in the same pulmonary lobe","volume":"39","author":"SILVA G.A.","year":"2013","journal-title":"Jornal Brasileiro de Pneumologia"},{"key":"ref30","first-page":"19","author":"SOLOAGA R.","year":"2010"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1086\/499057","article-title":"Current Treatment Strategies for Disseminated Candidiasis","volume":"42","author":"SPELLBERG B.J.","year":"2006","journal-title":"Clinical Infectious Diseases"},{"key":"ref32","series-title":"Caracteriza\u00e7\u00e3o da resist\u00eancia \u00e0 oxacilina em estafilococos coagulase negativa isolados no hospital de cl\u00ednicas de Curitiba \u2013 Paran\u00e1","author":"TERASAWA L.B.","year":"2006"},{"key":"ref33","series-title":"Microbiologia","author":"TRABULSI L.R.","year":"1991","edition":"2nd"},{"key":"ref34","series-title":"Background document for the Antiviral Drug Products Advisory Committee Meeting October 4, 2001: Voriconazole tablets and voriconazole injection. Pfizer Global Research & Development NDAs 21-66 and 21-267","year":"2001"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"WALSH T.J.","year":"2002","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1128\/JCM.02543-13","article-title":"Yeast identification algorithm based on use of the Vitek MS system selectively supplemented with ribosomal DNA sequencing: proposal of a reference assay for invasive fungal surveillance programs in China","volume":"52","author":"ZHANG L.","year":"2014","journal-title":"Journal of Clinical Microbiology"}],"container-title":["Brazilian Journal of Biology"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/bjb\/v78n1\/1519-6984-bjb-1519-698404916.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T18:43:59Z","timestamp":1520621039000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1519-69842018000100068&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,2]]}},"alternative-id":["S1519-69842018000100068"],"URL":"https:\/\/doi.org\/10.1590\/1519-6984.04916","relation":{},"ISSN":["1678-4375","1519-6984"],"issn-type":[{"value":"1678-4375","type":"electronic"},{"value":"1519-6984","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7,10]]}}}